<SEC-DOCUMENT>0001819790-21-000026.txt : 20210805
<SEC-HEADER>0001819790-21-000026.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210804173821
ACCESSION NUMBER:		0001819790-21-000026
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210804
ITEM INFORMATION:		Results of Operations and Financial Condition
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tarsus Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001819790
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				814717861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39614
		FILM NUMBER:		211145338

	BUSINESS ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		(949) 409-9820

	MAIL ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tars-20210804.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:86ab6f10-876f-4139-8b3a-d67b95c85294,g:54407c80-40ef-4ef6-ba28-1d09ac604373,d:01a2af4eb0c94b2c9f896eddbca82f9f--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>tars-20210804</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl80L2ZyYWc6MzJjZGZlMmFmNTRiNGExYmE4OWMxNmEyYWJiNGE0NDMvdGFibGU6YmJkZjMwZTk2NWFmNDMyN2E5YmQ5YzliNjEzNTA1ZTcvdGFibGVyYW5nZTpiYmRmMzBlOTY1YWY0MzI3YTliZDljOWI2MTM1MDVlN18xLTEtMS0xLTA_bb38ee56-e027-4ef1-ac3f-153d8a6fbe63">0001819790</ix:nonNumeric><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl80L2ZyYWc6MzJjZGZlMmFmNTRiNGExYmE4OWMxNmEyYWJiNGE0NDMvdGFibGU6YmJkZjMwZTk2NWFmNDMyN2E5YmQ5YzliNjEzNTA1ZTcvdGFibGVyYW5nZTpiYmRmMzBlOTY1YWY0MzI3YTliZDljOWI2MTM1MDVlN18yLTEtMS0xLTA_e1422fcd-0c06-482b-bb51-40de0bb05998">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="tars-20210804.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i01a2af4eb0c94b2c9f896eddbca82f9f_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">_______________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ2_0ce12764-c10a-4887-932e-02e6a0913f83">8-K</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (date of earliest event reported): <ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ3_ce18efb7-d9e0-4dde-bcce-bea922681a59">August 4, 2021</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">_______________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzUy_4ab01003-c2e8-4885-a3c1-b24b97de58a0">TARSUS PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">_______________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6MzY3MzJiODI4M2I3NGJkNDg0ZWY5OWMzYzIxZWIwMGEvdGFibGVyYW5nZTozNjczMmI4MjgzYjc0YmQ0ODRlZjk5YzNjMjFlYjAwYV8wLTAtMS0xLTA_ae47afe1-834a-4b09-9b5e-2b7271c16747">Delaware</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6MzY3MzJiODI4M2I3NGJkNDg0ZWY5OWMzYzIxZWIwMGEvdGFibGVyYW5nZTozNjczMmI4MjgzYjc0YmQ0ODRlZjk5YzNjMjFlYjAwYV8wLTEtMS0xLTA_92f185a9-6dbf-49e7-8b22-01e2accb56e4">001-39614</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6MzY3MzJiODI4M2I3NGJkNDg0ZWY5OWMzYzIxZWIwMGEvdGFibGVyYW5nZTozNjczMmI4MjgzYjc0YmQ0ODRlZjk5YzNjMjFlYjAwYV8wLTMtMS0xLTA_ebf86c73-81b0-4e87-8267-8acef2ec9fd7">81-4717861</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(State or other jurisdiction of incorporation)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(I.R.S. Employer Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ4_f0c28ea3-265f-474f-8f30-fae43d2782b2">15440 Laguna Canyon Road, Suite 160</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ5_f7e22708-02b3-47bb-b47f-fd722c12b82a">Irvine</ix:nonNumeric>, <ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzUz_a81b66a4-3597-4e5a-89cc-8d9a5eded095">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzUw_e23de752-a44b-4d73-8d70-2e50c93142f6">92618</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address of principal executive offices, including Zip Code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant's telephone number, including area code: (<ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzUx_9617e483-e8f0-4c7e-8fd2-00c11ef1b0ab">949</ix:nonNumeric>) <ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ1_43afcc04-c23a-4de8-8248-f07a5f329797">409-9820</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6NzllMmY1ZWMzMGYzNDRhMGI1ZDhmMjU3OWZjYjEwYTcvdGFibGVyYW5nZTo3OWUyZjVlYzMwZjM0NGEwYjVkOGYyNTc5ZmNiMTBhN18wLTAtMS0xLTA_83245549-63a8-44e4-8194-65b5283d2150">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6NzllMmY1ZWMzMGYzNDRhMGI1ZDhmMjU3OWZjYjEwYTcvdGFibGVyYW5nZTo3OWUyZjVlYzMwZjM0NGEwYjVkOGYyNTc5ZmNiMTBhN18yLTAtMS0xLTA_61f38247-2c44-47e0-936e-224f461e413c">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6NzllMmY1ZWMzMGYzNDRhMGI1ZDhmMjU3OWZjYjEwYTcvdGFibGVyYW5nZTo3OWUyZjVlYzMwZjM0NGEwYjVkOGYyNTc5ZmNiMTBhN180LTAtMS0xLTA_83eb2eae-05b4-42bd-89fe-67ffd0202956">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6NzllMmY1ZWMzMGYzNDRhMGI1ZDhmMjU3OWZjYjEwYTcvdGFibGVyYW5nZTo3OWUyZjVlYzMwZjM0NGEwYjVkOGYyNTc5ZmNiMTBhN182LTAtMS0xLTA_e59bf6aa-25f5-4495-b694-42720ae343e3">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6OTIzZGUyMTZlMWE3NDc3YTgzM2RkOTQ2M2UyYzA1NDYvdGFibGVyYW5nZTo5MjNkZTIxNmUxYTc0NzdhODMzZGQ5NDYzZTJjMDU0Nl8xLTAtMS0xLTA_721682bd-bd40-48a1-a11f-1044099bf067">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6OTIzZGUyMTZlMWE3NDc3YTgzM2RkOTQ2M2UyYzA1NDYvdGFibGVyYW5nZTo5MjNkZTIxNmUxYTc0NzdhODMzZGQ5NDYzZTJjMDU0Nl8xLTEtMS0xLTA_706ca617-2b8e-46d2-9959-4ad23baf4ee4">TARS</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Nasdaq Stock Market LLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6OTIzZGUyMTZlMWE3NDc3YTgzM2RkOTQ2M2UyYzA1NDYvdGFibGVyYW5nZTo5MjNkZTIxNmUxYTc0NzdhODMzZGQ5NDYzZTJjMDU0Nl8xLTItMS0xLTAvdGV4dHJlZ2lvbjoxZmUyZmI3ODg5NDI0NzA4ODQ3OTJiZGU5ZDQxYWVkN18zNA_9bf1989e-a6a9-4c8d-8c0c-4236a91d0d85">Nasdaq Global Select Market</ix:nonNumeric>)</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzU0_9666e442-73de-4625-a6d4-01b5137313cd">&#9746;</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzU1_48972b90-b6f1-44be-bfc1-557b412e95d2">&#9746;</ix:nonNumeric></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01a2af4eb0c94b2c9f896eddbca82f9f_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 4, 2021, Tarsus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release, which, among other matters, sets forth the Company&#8217;s results of operations for the three and six months ended June 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing information, including Exhibit 99.1, is being furnished under Item 2.02 and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01 Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)  Exhibits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.391%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit No.</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991tarsus08042021pr.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991tarsus08042021pr.htm">August 4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991tarsus08042021pr.htm">, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (embedded within XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01a2af4eb0c94b2c9f896eddbca82f9f_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TARSUS PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: August 4, 2021</span></div></td><td colspan="9" style="padding:0 1pt"><div style="text-indent:1pt"><span><br/></span></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Leo M. Greenstein</span></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Leo M. Greenstein</span></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991tarsus08042021pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i327a75feaf154ae38465ccbfea72a47a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><img alt="picture1a.jpg" src="picture1a.jpg" style="height:122px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis&#59; results presented at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) conference</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis&#59; Saturn-2 trial design similar to Saturn-1, topline data expected in Q1 2022</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Initiated the Phase 1 Callisto trial evaluating TP-05, a novel, oral, non-vaccine therapeutic, for the prevention of Lyme disease </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Cash and equivalents of $177 million, plus TP-03 license receivables of $20 million as of June 30, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">IRVINE, Calif., August 4, 2021 (GLOBE NEWSWIRE) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">-- Tarsus Pharmaceuticals, Inc. (NASDAQ&#58; TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results and provided business and clinical updates for the quarter ended June 30, 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We have achieved significant milestones on our lead product and pipeline so far in 2021 with the positive read-out of the Saturn-1 data for TP-03 in Demodex blepharitis, the initiation of Saturn-2, and the initiation of the Callisto trial of TP-05 for the prevention of Lyme disease,&#8221; said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus. &#8220;Interest from the physician community also continues to build, as new Saturn-1 data presented at the ASCRS 2021 Annual Meeting reinforced the strong potential clinical utility of TP-03 with a broad range of patients showing a substantial response. Additionally, results from the Titan and Atlas studies reinforce the prevalence and burden of Demodex blepharitis, suggesting that this disease could affect as many as 25 million Americans, with 80% of patients reporting a negative impact on daily life. We believe this data supports both the need and opportunity for an FDA-approved therapeutic treatment option.&#8221;</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Business Highlights and Corporate Update&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Announced positive results of the Phase 2b&#47;3 Saturn-1 pivotal trial studying TP-03 (lotilaner ophthalmic solution, 0.25%) in patients with Demodex blepharitis. All pre-specified primary and secondary endpoints were met, and complete resolution of Demodex blepharitis signs was demonstrated in many patients treated with TP-03 (lotilaner ophthalmic solution, 0.25%). </font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">81% of patients on TP-03 achieved a clinically meaningful collarette cure, defined as 0-10 collarettes per lid at day 43 compared to 23% of those on vehicle (p&#60;0.0001). </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">44% of patients on TP-03 achieved the primary endpoint of complete collarette cure, defined as 0-2 collarettes per lid at day 43, compared to 7% on vehicle (p&#60;0.0001).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">68% of patients on TP-03 achieved mite eradication defined as 0 mites per lash at day 43, compared to 18% on vehicle (p&#60;0.0001).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">Additionally, significant efficacy in lid erythema (redness) was demonstrated across multiple measures including complete and clinically meaningful composite cures, and in erythema alone. Results showed 45% of patients improved erythema by one (1) grade or more (compared to 28% of patients on vehicle, p&#61;0.0002) and 19% of patients on TP-03 achieved a complete erythema cure (compared to 7% of patients on vehicle, p&#60;0.0001). </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">TP-03 was well tolerated with a safety profile similar to the vehicle group. Additionally, the vast majority of TP-03 patients (92%) reported that the drop comfort was neutral to very comfortable. There were no serious treatment-related adverse events nor any treatment-related adverse events leading to treatment discontinuation. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Released new data from the Saturn-1 Phase 2b&#47;3 pivotal trial at the ASCRS 2021 Annual Meeting. The new Saturn-1 data reinforces the strong potential clinical utility of TP-03 for the treatment of Demodex blepharitis, with a broad range of patients showing a substantial response. </font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">95% of TP-03 patients showed a significant improvement in mite count, achieving &#8804;0.5 mites per lash at day 43 from an average baseline of 3.2 mites per lash, compared to 36% of those on vehicle (p&#60;0.0001).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">93% of TP-03 patients improved by at least one collarette grade or approximately 50 collarettes per lid by day 43, from an average baseline of grade 2.8 or approximately 100 collarettes per lid, compared to 50% of those on vehicle (p&#60;0.0001).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">An additional Saturn-1 safety analysis also revealed that TP-03 had no clinically significant effect on multiple safety measures including Corrected Distance Visual Acuity (CDVA), corneal staining, and intraocular pressure (IOP), and no significant findings from slit lamp biomicroscopy or fundus exam. In addition, no impact to endothelial cell density (ECD) was seen in a subset of 21 patients. ECD will be further evaluated as part of the Saturn-2 trial plan. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Presented data from the Titan real world prevalence study at the ASCRS meeting. The Titan study is an IRB-approved, retrospective chart review of 1,032 patients across six U.S.-based ophthalmology and optometry practices, designed to better understand the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">prevalence of collarettes in U.S. eye care clinics. Collarettes, or cylindrical dandruff, are a pathognomonic sign of Demodex blepharitis and are an accumulation of mite waste product and eggs that form at the base of the eyelashes. In data presented at ASCRS, the Titan study revealed the presence of collarettes in 58% (n&#61;595) of patients. When projected across the U.S. population, these results suggest that Demodex blepharitis could affect as many as 25 million Americans. The study also revealed that the prevalence of Demodex blepharitis is similar to that of dry eye (58%, n&#61;593). </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Commenced enrollment in Saturn-2, the second pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Saturn-2 is a randomized, controlled, multicenter, double-masked trial studying the safety and efficacy of TP-03. The trial is expected to enroll 418 participants and has a similar design to Saturn-1. Saturn-2&#8217;s primary endpoint is the proportion of patients achieving collarette cure, defined as 0 to 2 collarettes per lid. Secondary endpoints include the eradication of Demodex mites and the proportion of patients achieving a cure based on a composite of collarette cure and erythema cure (eyelid redness). Topline results for the study are anticipated in Q1 of 2022.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Initiated the Phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic, for the prevention of Lyme disease and malaria.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Phase 1 Callisto trial is a single ascending dose and multiple ascending dose trial designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of TP-05 in healthy volunteers. There are currently no U.S. Food and Drug Administration (FDA)-approved pharmacological prophylactic options for Lyme disease, which is the most common vector-borne disease in the United States, transmitted to humans through the infection of the bacterium Borrelia burgdorferi following the bite of a tick vector.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Presented data from the Atlas study at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Atlas study is believed to be the first multi-center observational study to evaluate the functional and psychosocial impact of Demodex blepharitis, along with clinical manifestations, in adult patients. Overall, the study showed that Demodex blepharitis is associated with a significant symptomatic and psychosocial burden, negatively affecting daily life in the majority (80%) of patients with the disease. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Received $35 million in proceeds as part of the partnership with LianBio&#59; an additional $20 million is expected in Q3 2021 for clinical milestones achieved in June 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second Quarter 2021 Financial Results</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Second quarter net income for 2021 was $6.3 million, compared to a net loss of $(3.3) million for the same period in 2020.  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Second quarter 2021 license fee and collaboration revenue, as part of strategic partnership with LianBio, was $22.0 million&#59; and $0.7 million in associated expense in proportion to this revenue. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Second quarter research and development expenses for 2021 were $7.2 million (inclusive of stock-based compensation of $0.4 million), compared to $1.7 million for the same period in 2020. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Second quarter general and administrative expenses for 2021 increased to $6.8 million (inclusive of stock-based compensation of $2.4 million), compared to $1.5 million for the same period in 2020. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;As of June 30, 2021, cash and cash equivalents were $176.7 million, and accounts receivable were $20 million for an achieved TP-03 clinical milestone.  </font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">About Tarsus Pharmaceuticals, Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The Company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#8220;forward-looking statements.&#8221; These statements include statements regarding the receipt by Tarsus of future payments and achievement and timing of milestones under the terms of the collaboration with LianBio, the ability of LianBio to commercialize TP-03 in the Greater China territory,</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the market size for TP-03 and TP-05, future events and Tarsus&#8217; plans for and the anticipated benefits of its product candidates including TP-03 and TP-05, the timing, objectives and results of the clinical studies, anticipated regulatory and development milestones and the quotations of Tarsus&#8217; management. The words, without limitation, &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Important factors that could cause actual results to differ materially from those in the forward-looking statements include&#58; Tarsus has incurred significant losses and negative cash flows from operations since inception and anticipates that it will continue to incur significant expenses and losses for the foreseeable future&#59; Tarsus may need to obtain additional funding to complete the development and any commercialization of its product candidates, if approved&#59; Tarsus is heavily dependent on the success of its lead product candidate, TP-03 for the treatment of Demodex blepharitis&#59; the COVID-19 pandemic may affect Tarsus&#8217; ability to initiate and complete preclinical studies and clinical trials, disrupt regulatory activities, disrupt manufacturing and supply chain or have other adverse effects on Tarsus&#8217; business and operations&#59; even if TP-03, TP-05, or any other product candidate that Tarsus develops receives marketing approval, Tarsus may not be successful in educating eye care physicians and the market about the need for treatments specifically for Demodex blepharitis, Lyme disease, and&#47;or other diseases or conditions targeted by Tarsus&#8217; products&#59; the development and commercialization of Tarsus products is dependent on intellectual property it licenses from Elanco Tiergesundheit AG&#59; Tarsus will need to develop and expand the company and Tarsus may encounter difficulties in managing its growth, which could disrupt its operations&#59; the sizes of the market opportunity for Tarsus&#8217; product candidates, particularly TP-03 for the treatment of Demodex blepharitis and MGD, as well as TP-05 for the treatment of Lyme disease, have not been established with precision and may be smaller than </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">estimated&#59; the results of Tarsus&#8217; earlier studies and trials may not be predictive of future results&#59; any termination or suspension of, or delays in the commencement or completion of, Tarsus&#8217; planned clinical trials could result in increased costs, delay or limit its ability to generate revenue and adversely affect its commercial prospects&#59; and if Tarsus is unable to obtain and maintain sufficient intellectual property protection for its product candidates, or if the scope of the intellectual property protection is not sufficiently broad, Tarsus&#8217; competitors could develop and commercialize products similar or identical to Tarsus&#8217; products. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus&#8217; Form 10-K for the year ended December 31, 2020 filed with the SEC on March 31, 2021, and Form 10-Q for the quarter ended June 30, 2021 filed with the SEC on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">August 4, 2021</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus&#8217; management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SuJin Oh</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shop PR</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(917) 841-5213</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sujin&#64;shop-pr.com</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investor Contact&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Patti Bank</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Westwicke Partners, an ICR company</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(415) 513-1284</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IR&#64;tarsusrx.com</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,048&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,359&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,969&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,090&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,017&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,449&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of license fees and collaboration revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,034&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,204&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,737&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,465&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,249&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,794&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,526&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,954&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,132&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,735&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,263&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,453&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,381&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from operations before other (expense) income and income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,282&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,263)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,996&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,381)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity warrant rights</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(876)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(876)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other (expense) income </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(908)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(933)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(342)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) and comprehensive income (loss)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,345&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,250)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,721&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,207)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share </font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.23)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.81&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.96)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.29&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.23)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.96)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding </font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,555,258&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,651,321&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,446,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650,843&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966,599&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,651,321&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,895,304&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650,843&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In thousands, except share and par value amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,735&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,129&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,012&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,904&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,655&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">688&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,525&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,450&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,972&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,985&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,347&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,455&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,387&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">524&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,979&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,992&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and contingencies (Note 9)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.0001 par value&#59; 10,000,000 authorized at June&#160;30, 2021 and December&#160;31, 2020&#59; no shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $0.0001 par value&#59; 200,000,000 shares authorized&#59; 20,704,104 shares issued and 20,573,951 outstanding, which excludes 130,153 shares subject to repurchase at June&#160;30, 2021 (unaudited)&#59; 20,502,576 shares issued and 20,323,301 outstanding, which excludes 179,375 shares subject to repurchase at December&#160;31, 2020</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,591&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,821&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,124)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,845)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,471&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,980&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities, preferred stock and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,450&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,972&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tars-20210804.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:86ab6f10-876f-4139-8b3a-d67b95c85294,g:54407c80-40ef-4ef6-ba28-1d09ac604373-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tars="http://tarsusrx.com/20210804" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://tarsusrx.com/20210804">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20210804_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20210804_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://tarsusrx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>tars-20210804_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:86ab6f10-876f-4139-8b3a-d67b95c85294,g:54407c80-40ef-4ef6-ba28-1d09ac604373-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_99c81ca4-d0e9-43e7-9033-fd21572405d3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b4fd8748-b961-45cd-8b95-b0606c6617cd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a2cddcb6-66e8-47bf-bb71-f7b5a1bb72ca_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_09961715-5a58-4730-bb38-b6d83a5455d5_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e90fc777-294f-4eac-af5d-460221d87b4b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a0143a92-3257-4d90-835d-aa633078ae7f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8e7b73c0-b8bd-4b54-ad27-4a1b371ab92b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_abb8499a-85ab-4ed7-beea-7c077ab7ee8b_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_5ea353bf-fb90-4d1d-8c31-f5450cee41e0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2e6750ac-c947-4fff-bc02-48c125ec0dec_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_99f30663-b441-4aad-8384-8a965e9b7547_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_87fbb10b-57bd-48a0-9747-dd12b6f858d5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_7584413b-1ebf-4d0f-8005-efdf2650289e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4a723ff7-86e7-4194-a7de-dafa190c36fc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_34dcece1-bd0b-4132-aafe-32578d91a2f9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9dd7e7b7-4e6c-493a-907d-c760bfc3e52d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6ebf4f29-ced4-486f-8b1a-51214e0ccd08_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ff02cf48-b962-4851-a376-c41bf1a1782d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f7c9e1ed-5f04-4b8f-a5d6-9a00ecaaa8f8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_039c57c5-8868-43a5-b9d4-2eb79533d27b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_32a14195-dc50-4d9b-8368-f3c853db784b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_93fc6a71-bfc2-40fa-b8d8-24a5847aa3c6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0c27e5a6-2f4b-4f35-9418-4d831dd56b44_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>tars-20210804_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:86ab6f10-876f-4139-8b3a-d67b95c85294,g:54407c80-40ef-4ef6-ba28-1d09ac604373-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tarsusrx.com/role/Cover" xlink:type="simple" xlink:href="tars-20210804.xsd#Cover"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a991d455-0cbb-4334-879b-1fc682fa139a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_DocumentType_a991d455-0cbb-4334-879b-1fc682fa139a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_63fd6c34-a771-4a3a-99d9-6ecc7c211036" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_DocumentPeriodEndDate_63fd6c34-a771-4a3a-99d9-6ecc7c211036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cfd03e79-4529-4297-95eb-86e087756159" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityRegistrantName_cfd03e79-4529-4297-95eb-86e087756159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c318cea2-4888-433f-a760-f852f518d3d8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c318cea2-4888-433f-a760-f852f518d3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fd4eca4f-eb34-4fdf-839c-52b38a0c1e96" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityFileNumber_fd4eca4f-eb34-4fdf-839c-52b38a0c1e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1724e6ef-3925-46f9-9db6-be7725a08bc2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityTaxIdentificationNumber_1724e6ef-3925-46f9-9db6-be7725a08bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3bd41453-c414-4732-8122-c668a5c8e82d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityAddressAddressLine1_3bd41453-c414-4732-8122-c668a5c8e82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f7c74f0d-3e54-4958-a079-3263e2b57241" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityAddressCityOrTown_f7c74f0d-3e54-4958-a079-3263e2b57241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2a905beb-309b-42ac-926c-fb0a83fc1008" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityAddressStateOrProvince_2a905beb-309b-42ac-926c-fb0a83fc1008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fd5445c4-d8ad-44cb-a127-49cd2d5746ec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityAddressPostalZipCode_fd5445c4-d8ad-44cb-a127-49cd2d5746ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a09ce9ce-1adc-459b-a9d8-0bad9cd5df97" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_CityAreaCode_a09ce9ce-1adc-459b-a9d8-0bad9cd5df97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3c45ab89-2cee-4ca7-aebd-2ea49956cddc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_LocalPhoneNumber_3c45ab89-2cee-4ca7-aebd-2ea49956cddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ad5bde1f-2da5-43e4-a1c1-492423cdfe3d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_WrittenCommunications_ad5bde1f-2da5-43e4-a1c1-492423cdfe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b1eeef00-d628-44e9-bd60-c0e9bc722602" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_SolicitingMaterial_b1eeef00-d628-44e9-bd60-c0e9bc722602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f2656cd4-6c67-4dbf-bc9e-9914228cbcb6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_PreCommencementTenderOffer_f2656cd4-6c67-4dbf-bc9e-9914228cbcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3a9f9d26-2e7b-44fa-876a-337876cca5f6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3a9f9d26-2e7b-44fa-876a-337876cca5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_72957f3f-e0cb-4fa1-8a24-8de178b9ddfe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_Security12bTitle_72957f3f-e0cb-4fa1-8a24-8de178b9ddfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e5be3690-3132-44f1-b924-de9d20e77a67" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_TradingSymbol_e5be3690-3132-44f1-b924-de9d20e77a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ff6da6de-8cb3-4590-90ba-74566573a3c9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_SecurityExchangeName_ff6da6de-8cb3-4590-90ba-74566573a3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a63ca0d2-e31c-44af-a002-7292da9fe70a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityEmergingGrowthCompany_a63ca0d2-e31c-44af-a002-7292da9fe70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_00f76174-be61-4634-b513-de25f9cb4c47" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityExTransitionPeriod_00f76174-be61-4634-b513-de25f9cb4c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e89c2f85-eee9-4ee9-bf02-fab48a4346a9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_EntityCentralIndexKey_e89c2f85-eee9-4ee9-bf02-fab48a4346a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_183222d0-531f-4246-9729-dbb5f59be793" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d6b7d20-5bce-486e-91b2-2a300403277c" xlink:to="loc_dei_AmendmentFlag_183222d0-531f-4246-9729-dbb5f59be793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>picture1a.jpg
<TEXT>
begin 644 picture1a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !Z *@# 2(  A$! Q$!_\0
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MZ5TX[#U,1-5J2YHM'+EV)I86FZ%9\LDSS_\ X*Z?\?/PX_W+S^<5?2G[*O\
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MB(#;N/'WL$9/'S9J*T*6'K4:J7+?==BZ%2MBJ%:DY<UMGW/&/^"6#!OV?=2
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0'#482YHP2?H@HHHK Z#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>tars-20210804_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tars-20210804.xsd" xlink:type="simple"/>
    <context id="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl80L2ZyYWc6MzJjZGZlMmFmNTRiNGExYmE4OWMxNmEyYWJiNGE0NDMvdGFibGU6YmJkZjMwZTk2NWFmNDMyN2E5YmQ5YzliNjEzNTA1ZTcvdGFibGVyYW5nZTpiYmRmMzBlOTY1YWY0MzI3YTliZDljOWI2MTM1MDVlN18xLTEtMS0xLTA_bb38ee56-e027-4ef1-ac3f-153d8a6fbe63">0001819790</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl80L2ZyYWc6MzJjZGZlMmFmNTRiNGExYmE4OWMxNmEyYWJiNGE0NDMvdGFibGU6YmJkZjMwZTk2NWFmNDMyN2E5YmQ5YzliNjEzNTA1ZTcvdGFibGVyYW5nZTpiYmRmMzBlOTY1YWY0MzI3YTliZDljOWI2MTM1MDVlN18yLTEtMS0xLTA_e1422fcd-0c06-482b-bb51-40de0bb05998">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ2_0ce12764-c10a-4887-932e-02e6a0913f83">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ3_ce18efb7-d9e0-4dde-bcce-bea922681a59">2021-08-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzUy_4ab01003-c2e8-4885-a3c1-b24b97de58a0">TARSUS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6MzY3MzJiODI4M2I3NGJkNDg0ZWY5OWMzYzIxZWIwMGEvdGFibGVyYW5nZTozNjczMmI4MjgzYjc0YmQ0ODRlZjk5YzNjMjFlYjAwYV8wLTAtMS0xLTA_ae47afe1-834a-4b09-9b5e-2b7271c16747">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6MzY3MzJiODI4M2I3NGJkNDg0ZWY5OWMzYzIxZWIwMGEvdGFibGVyYW5nZTozNjczMmI4MjgzYjc0YmQ0ODRlZjk5YzNjMjFlYjAwYV8wLTEtMS0xLTA_92f185a9-6dbf-49e7-8b22-01e2accb56e4">001-39614</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6MzY3MzJiODI4M2I3NGJkNDg0ZWY5OWMzYzIxZWIwMGEvdGFibGVyYW5nZTozNjczMmI4MjgzYjc0YmQ0ODRlZjk5YzNjMjFlYjAwYV8wLTMtMS0xLTA_ebf86c73-81b0-4e87-8267-8acef2ec9fd7">81-4717861</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ4_f0c28ea3-265f-474f-8f30-fae43d2782b2">15440 Laguna Canyon Road, Suite 160</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ5_f7e22708-02b3-47bb-b47f-fd722c12b82a">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzUz_a81b66a4-3597-4e5a-89cc-8d9a5eded095">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzUw_e23de752-a44b-4d73-8d70-2e50c93142f6">92618</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzUx_9617e483-e8f0-4c7e-8fd2-00c11ef1b0ab">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzQ1_43afcc04-c23a-4de8-8248-f07a5f329797">409-9820</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6NzllMmY1ZWMzMGYzNDRhMGI1ZDhmMjU3OWZjYjEwYTcvdGFibGVyYW5nZTo3OWUyZjVlYzMwZjM0NGEwYjVkOGYyNTc5ZmNiMTBhN18wLTAtMS0xLTA_83245549-63a8-44e4-8194-65b5283d2150">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6NzllMmY1ZWMzMGYzNDRhMGI1ZDhmMjU3OWZjYjEwYTcvdGFibGVyYW5nZTo3OWUyZjVlYzMwZjM0NGEwYjVkOGYyNTc5ZmNiMTBhN18yLTAtMS0xLTA_61f38247-2c44-47e0-936e-224f461e413c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6NzllMmY1ZWMzMGYzNDRhMGI1ZDhmMjU3OWZjYjEwYTcvdGFibGVyYW5nZTo3OWUyZjVlYzMwZjM0NGEwYjVkOGYyNTc5ZmNiMTBhN180LTAtMS0xLTA_83eb2eae-05b4-42bd-89fe-67ffd0202956">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6NzllMmY1ZWMzMGYzNDRhMGI1ZDhmMjU3OWZjYjEwYTcvdGFibGVyYW5nZTo3OWUyZjVlYzMwZjM0NGEwYjVkOGYyNTc5ZmNiMTBhN182LTAtMS0xLTA_e59bf6aa-25f5-4495-b694-42720ae343e3">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6OTIzZGUyMTZlMWE3NDc3YTgzM2RkOTQ2M2UyYzA1NDYvdGFibGVyYW5nZTo5MjNkZTIxNmUxYTc0NzdhODMzZGQ5NDYzZTJjMDU0Nl8xLTAtMS0xLTA_721682bd-bd40-48a1-a11f-1044099bf067">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6OTIzZGUyMTZlMWE3NDc3YTgzM2RkOTQ2M2UyYzA1NDYvdGFibGVyYW5nZTo5MjNkZTIxNmUxYTc0NzdhODMzZGQ5NDYzZTJjMDU0Nl8xLTEtMS0xLTA_706ca617-2b8e-46d2-9959-4ad23baf4ee4">TARS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGFibGU6OTIzZGUyMTZlMWE3NDc3YTgzM2RkOTQ2M2UyYzA1NDYvdGFibGVyYW5nZTo5MjNkZTIxNmUxYTc0NzdhODMzZGQ5NDYzZTJjMDU0Nl8xLTItMS0xLTAvdGV4dHJlZ2lvbjoxZmUyZmI3ODg5NDI0NzA4ODQ3OTJiZGU5ZDQxYWVkN18zNA_9bf1989e-a6a9-4c8d-8c0c-4236a91d0d85">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzU0_9666e442-73de-4625-a6d4-01b5137313cd">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYTJhZjRlYjBjOTRiMmM5Zjg5NmVkZGJjYTgyZjlmL3NlYzowMWEyYWY0ZWIwYzk0YjJjOWY4OTZlZGRiY2E4MmY5Zl8xL2ZyYWc6ODc2YWVkMjljYmI1NDE5NWE0ZWI4N2UwMjc5MTlhNzYvdGV4dHJlZ2lvbjo4NzZhZWQyOWNiYjU0MTk1YTRlYjg3ZTAyNzkxOWE3Nl8xMzU1_48972b90-b6f1-44be-bfc1-557b412e95d2">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140200474829480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  04,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TARSUS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-4717861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15440 Laguna Canyon Road, Suite 160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">409-9820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TARS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MNFI_E-XWM$R+X^M":C@,%[=K1L''S OP^U)*?6R8$W'Y#XW1/U!+ P04
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #'C 13!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( ,>,!%/Y>*E-[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,>,!%.97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MQXP$4WS<U*9<!   W!   !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,>,!%.?H!OPL0(  .(,   -
M          "  : ,  !X;"]S='EL97,N>&UL4$L! A0#%     @ QXP$4Y>*
MNQS     $P(   L              ( !? \  %]R96QS+RYR96QS4$L! A0#
M%     @ QXP$4ZK$(A8S 0  (@(   \              ( !91   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,>,!%,D'INBK0   /@!   :
M      "  <41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( ,>,!%-ED'F2&0$  ,\#   3              "  :H2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /03      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tars-20210804.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tars-20210804.htm">tars-20210804.htm</File>
    <File>exhibit991tarsus08042021pr.htm</File>
    <File>tars-20210804.xsd</File>
    <File>tars-20210804_lab.xml</File>
    <File>tars-20210804_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tars-20210804.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tars-20210804.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tars-20210804_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tars-20210804_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tars-20210804.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "tars",
   "nsuri": "http://tarsusrx.com/20210804",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210804.htm",
      "contextRef": "i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://tarsusrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210804.htm",
      "contextRef": "i05c349d5848a4e0f95e42ddacd735d4c_D20210804-20210804",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001819790-21-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001819790-21-000026-xbrl.zip
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M\W-#@)$?^=P=LX<A $O@;1@B;^T0K5 ?<" PV66Q.Q(1<X6PI /GON^,09U
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M6Y5A@V2XTZH9KRS#QJP,MYJX\+:>]VO 7\F3%!_R%!> 1QL)[L(@_1B!O^,
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MB+*;-(IDQZ1C'C%WS3!FX\72V#W1V*W4PI]T<SYKZS[*RHB#^-A\7>MW9X]
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M!2I.%LSNWH@P"FP3X"=9WK?PZJNMOSAF"U6 7>&-42OL^WQV%%AU39/RI"R
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M"*JP"Z\X/>IYUAC^&48CY\/_ U!+ P04    " #(C 13@II?@'@5  !9C
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MA=@;CGP!B^EO_4@(RQ+P%">Q R1*RS2R]J\;S7F(PW&4?DM1O)Q+8"84CY'
M.2&>HLO\F^>([Z['(Y0RQ-<JS_WZW\N+Y>;#>_.?EJF/8'Q#9_X-U$:45,'&
MV!-,"94KL/AFV16;SBU5YR7S[_-&2DL#-1_5JV$L+<!X"< ^0_QL..\Q,TY)
M8?&97$L,O0#WN3"%RHHZ2CY>>D[2+Q-)^K]"6F_O4SQB(%%65(*GL\\9D152
M@F',?.\L*-LP@CP""@FS?#ZO8(41,([MT/?9*.;E^8>/<U65Z5F</O1QR*(S
M8,X*DR0<E@5O8/TEGLW\O)&TO:SXFNVBE+&>P  ESKSEO+B8%I429[7,-(JF
M='NQ5"179:64=C2OD(^>/$H*Z7/0*S%,GPMRX4;'\ZY 3>2$8S$P?P"W'T?,
M<;S@K"PADM*X;J24CL2Z6<O&)@E'94)A9-8-O6!B7A]X"J.R:$TTZ()P89<-
M/7]:_F?'&P)$-/DE:H=#%OQS-P9[# S0R'.SBK$WXV6B02OIU\NLNSK022<K
M[SZA8O".F_5.K8J..I5.[6A97.X1E)?@]JBV?]RN=^JU(U1I5E'M/_O_KH 6
M0/NM1J-^=%1O-5^P"V2C+IRPN ^RDX3!+JH6]XO@SZB*^8)LTQML*S?9)BJP
M?;K\[U9^7ZN<?VFU&VB+QO/<G<W<@I<TH29S$ZI5M6GWY,=Y8^ /NL,Z:59K
M:O.D)F@H37I\V1C8:J/C]YNS+IA#/Q3GWU_]'O4OK$&H-&>]?N_D^[1UTO2Z
M@V.IT3DGW8[@]TSN=2K3YNQ\TCJI 7?&I#'[3D\EFQ.J:PJVB<3 #C)T;,J4
M@V/(-2:91'8-,'P-_/=-*P@]M2A1F;ATFRL8(*A=:W90N_:MU>[\[,K=.KO?
MQE$\9D&"DA =<5OX[(C(J-5&1-UQ/J#019T^%T7CR$L\:+@VL?M@?')4L1-1
M3$Q9>44+?K-N"UM-,-_FHS!*T(Z3?^<,K#4>)XA?B.A3E!9SYT/YZ=%AT?<2
MS0^!8M]ATRGPP(-UZ/$MM2EKF:7Y^\&(? HH8G#7TK%C<@DKX!MAR[;A/\Y,
M2C6#,-4L[%7&9V.8064W#0:N^E6O1E3?N&ZE-_E?O]2V'I-J\S,O%F''I DE
MO]VZ.)Z>*LR2P%>2L4VY(=2KBIEL$VQ1Q3)UAZL&DPI[G4K[Z/@(??MWI=VH
M[->.._7]RN'1+JHW]XL;KY+MKPII(ZG:J4T8Z!\A"P*WHRL90"Q&\8C;(@+@
M("] 7A(CT%@ X]&'7\:0?GG?W#2+ABH_QC67]:)FFANYY@\A:Q1UZ:U0_8DA
MN*N,%@%)'Q+SN"W ,0]AT-%$!#%6=<F*?(2CIUXQYGTXD"Z8;9IE8MM.Q  3
M/HK""P$URW99IG[J@1U&8":F^UU'HO9^. Z2:+H?.F]3&V7Q\L8,.)U]]5K5
MNM*@=;EY\/6\63V#9[IJZP1*9_6)X*%Q4+L1+P]GS8$]:PSAN<'9K#NPI>[P
MN]2JMOW>X%SM0FEC\ 7Z6[GL_C N#SN5JW@YXXK.7$ZP(2O@)UJ2B4U+Y9A:
M.M6)331=T<%XYSZ[!"/Y5J652_^58&N;"+;/W5782\5ZO9&E/8>-=>\BD/3G
M,+&^>#X'ZA9T\%V@[Q?HZPT@D[K$4)F)-<=RL6)R'1L6I5@BG#+;ME2-*V(3
M@V#9U(ARMQFV(M?O@+U&5CML4L^W@.P4D]\%=V/!;5SO7%JNH=FZC UB@:O-
M#1!<JL%_S.8NY;;I.H#$!L&*3G1#N]W-OE]F5_=)7K=AHF\DYSNI*8#""(5)
MGT=H,(Z\V/&R"!MX+-ZBV?#AYU37:^OZ?C@<>K'([$)"<Z!L!=[>R3<YO_5B
MNWA41+7AR ^G,,'+H(.:8?$A'7[<9J'^+('OS3SRK0-[Q7$B'L?YGT-@@+Q)
M4/^I(*ARZDHV-3B3,=54,"ETQ<6&*TLPJ5R1':H;U**%/2*2&=$A.QL'#.VS
M8 HBV0Z9LXN.QA[@$M%6LXM>;J_B=4G8/GQL19WP,OC]Y$L]=75.J2Z26Z@E
M@WQ9%K84W<6@\"FU";4,R@I[]>@"YN>F".UN<Q-U:8Y2[=J*OH%C[J5IG[_9
M1!W/3AF89IK&%"RKIL@F5!DV3-O&AF,RE3O<D4RUL+=?6=U3?:8Y^A;&"?-[
MWNC-1D)^:H8N3SF5':ZK%#-%L;#B"'/:T25,N2K9IDP4ZFJ%/9-JQ'@]8'RO
M^9/%W_,Y%J;L*((EZ(V8C_B$V^/$NQ Q>;"$>+PK[%Q_+$P<!(* A"3<'H5_
M_BVXS13/]0[3/V.4<)^/^F' 49":M8M=9!%GL)X<7D8[6UQE0D%5H*G?<UU-
M3DV-Z%PQ9,P-%YQ36^=@ CD42Y)-"'?!8V46K"N1.+6\JCYL$_L.0W!+O@G)
M>,,1AY\R'LBI(C/7MF& ;"HS0#QN8(,J!G8EG:FN3$W=U M[BHCK&G1S"_0&
M,&P=!E8VY[+4GCZWSQ%X\XB-1E$(L"<\?"N<((O[X27RW+3P2Q@-D8'_1J[G
M"U#P8D"(A >@D4663>P-QW[" AZ.8W^*8G 78W>:/ID_$%H >6P>*! %"]N;
M8Z 3(3#HYV5NZ$/CXCFQ2^$)KSLN/V D7U5*[SV[6[K^Y%MQIE8D5-[RIMFZ
MO85L6!:SLK<6B5T1Y^WL&MS<.A,G2BP&TIG &EE$RI/(2V!!B##1.,@#)O&;
MA,LL0-N<^3[0(;V3QJQQT)TUJ^U^XZ!.>M7^L#$XEELGO4%W4+OLKAPM":'L
M&'C^ ?PV+GN#AM0\@'J#'^>M@^ZTV;'5WK#I-3I_]9MD>:O,D*FBJHJ)-9D9
M6%&X@@UB*EA3+94:LD.)*A7V_OS#U!7EXS;V%>Z3Z76((ST]=M\OZVE>=29Q
MT,5%D4.CA>S']AA@4*%JCK#)<M:C2';<(3K:_])&5):*4/'#FE%\^%F"M0'
M9PF8OX/2$B@=A;YGPV0'9PU0ZZ#;_7=$N@^1IHN(I!%7!F-/Q]16%*SH7,*F
MK'%,J>(J&N$*D>VW@TB/=Z W0Z1K<4/#7-Y6X8@H#!.Z@$A+R==7>*2 E9+6
M_!4A:>@YCL^79S G@47],C'F1+Q [,&4L?AE<SU3$6/_1D'K6\2%%26.:*;G
M2X27$;5<]XUZG\\*7M*R.<4MRAG'DFH!>%'+P8;I<JSIKNM(,#.FJKV#UQR\
M0.RPO2!W]]I51'$PW;$^; 9E6=U?$<PVF-&/3PIN3SGKKP;FZG$\YM$[V#T
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M$95^(Q\_@.D<CT%S,5!BXL@3+!_.8KZ;Q8UW$1N&(FL_-;I!M8"  M&8P[R
MK@%E*2@OD"3Z1T'C:N;"ZYD3FE;43OH1Y^D\QMX$I3=#@N).U?/7<<"1+&5]
M*J(*H,CHZBS $G^IQ9\D#"P"!P%O'!0N$T9WW[.\!)EFD:1-I.<3YI<1Y%7!
M!P!;XNKZ]X>(SNTB\(:EJ9,>M !+*DQ/= 17+SA9//VU.+*[8E@M+GYVQU'@
MQ6(2LOW@Z^6;3G"?^7YJC%D<7#"P\9RY&+J>SYU<"%/1 -,) )FG4G-E.AD;
M.E:[8O+9,)6BW:M[*2[!=D/QV!H([Q@$1!#R/69Y/EA &666@##;66>#,,HY
M]A897I*?1<$1SJ2P%?.3+;>F5N<>Y3*/?&+S47:A7]JD):S45,3%N1F>Y,L+
MVLLO_+.7&X['-EBJ>=NK(GRG4+X@LIM%B2S@=WK26>0=9,">"UG\ROIS2XS.
M^8#NY/C9[RS4LX3-AQI]M$BH^O2[^DH1')4G)PM J3V.ZMUEIK[9.:F']8-J
MVBOB]<YQE8NR\3AF7XBLN=GPK?=3B+K%M,KWJC^;@VH^V:6&BU86>3$3:VX]
M-</B/2F&JSV_=6#-6SSK+6WHO?@@5GEL1]Y(&&NW9T_?=L/8<VUXIF]J_/@Z
M!DS8ZAMGM&XT0!O(XL/%=HMSLLD4N.[6IB!CVN%V?A5>.?411"U@AZT-R/ ,
M*3Z^.(,H>YU:SH]IDB2-,(@XL_#.1U&QGPS3!&+PRMNY5^ZD3M*G$OM5NC</
ML_Q"79J_.H*MRW;?,!/V <I^S?K-,/*V%/EG1LHTA$HD98.4FM=I0#W.;KH!
MC\^0JK:ATMH/@17TC9UQ5!<).+#$Q)U+59:P[,+-'3ZTN./D[TWV I2^5-G)
MWR/S836_]=?9/R#2:]A N+F2'QP!?:;[KM;+UU']H%GI'+<?\<Z_!\=X7ZB+
MB^^]RC;)_SOVHCS.MFE =<WNNC/VI\AF8[$CGF:M9*^0$LU8',70<2@(L[>2
M6+S/?%?$+P6A5$GE%40(?AS ,RDY-D[Z802=<YYN"^?90V^D2*GQN-";LH70
MFP*%RN-N$[J[3%$>^^2=03*%;B-,:#Q]F' [O,I%]9&S=8\0R/J#0F2OS)9Y
M\:J/?K/&,YFRJ^_+$-)P]YNP5L_^O =&WZ.=3QVH8PDOHYNO*GQDV//>WJVU
M66]?R[]'K+04E^[*)-[V^85#'J)&$1U$G =QPKV- [:/BB,^ ,F?,N2X[O*>
M+<_^&Q_]7V-M[?<][BXD,;32ZZ"C]T%^X""G%,M> GS8F^1;?+NZBGME[-/L
MD>ORRG62=E[AX:=@7DEPJ&2%SA3^]).AO_?_4$L#!!0    ( ,B,!%-S2Z>5
M:@(  &('   1    =&%R<RTR,#(Q,#@P-"YX<V3-55MKVS 4?L^OT/P\^1*[
MB6V:%-92&&0;="WMVY#EXT34ECQ);MQ_7TF)R:7MNL >!H%(YWS?N1_Y_*)O
M:O0$4C'!9U[DAQX"3D7)^'+FW=U>X]2[F(]&YY\P?OARLT!7@G8-<(TN)1 -
M)5HSO4+W):A'5$G1H'LA']D3P7CN2)>B?99LN=)H'(ZC8ZW,TPDI)E44XG0Z
MJ7 2Q1E.BYC@<C(MLC.:GHVSY/,R/TN2<$K3$"<A&!A4$UR0<8JC,LP(G81)
M/(V=T5[EBJZ@(<@DQE7>JYFWTKK-@V"]7OOKV!=R&8S#, H>OBU^.JBWQ=:,
M/QZ@^T+6 SX.K+H@"@:X)G)GW%XZ)7N?BB:PJ89IF'B(:"U9T6FX%K*Y@HIT
MM9YY'?_=D9I5#$I3[AIL00\ >VIC> GZ.VE M83"!P[G(X1L#5C3"JD1?T7;
M*T*495G0VZP\M*G90E"BW2"\6P2'Q_:(HS&.([]7I1?\E=M#0XPK33B%4WR;
M&QYX_R*&74=/BV'@G1Z#,Z: ^DOQ%)3 7.?>=J_>@]L#MH=#GX1SH1W?2K:R
MMF6\$AN!$=G \R'Z&ZB&)7DU^6^,B/O+B:12U!_,4]!*T8+4#-3^UC@#*PG5
MS+/3BX>I_563PC>1#)!7#@Y;8-6!H4"]V&4R</5S:[C*-*"&36W^Y\1;":<F
M;BC*/!>NT2?F;_FW1H]8.?,NA7GU/61E=S=?WWY6G,,-<+ TV"JA8IRY:0O-
M8VI^".\^#A@YUGEPC#VRTBDH?_"Y.Q\GMB5O(7\@4E+3KCZ=MPOK7=I6.!1N
MNUC!X69M[GO;YP2;E9Z/7@!02P,$%     @ R(P$4WG>!8"M"@  _V   !4
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MSBF*8P8H9MQ,HB4!7"D&B/ )89PH10>3V=G#L>&Y%NDU50Y'M-O&W9R.-N?
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M<BYH=&U02P$"% ,4    " #(C 13@II?@'@5  !9C   $0
M@ &2)@  =&%R<RTR,#(Q,#@P-"YH=&U02P$"% ,4    " #(C 13<TNGE6H"
M  !B!P  $0              @ $Y/   =&%R<RTR,#(Q,#@P-"YX<V102P$"
M% ,4    " #(C 13>=X%@*T*  #_8   %0              @ '2/@  =&%R
M<RTR,#(Q,#@P-%]L86(N>&UL4$L! A0#%     @ R(P$4U5?Y$7=!@  ZS(
M !4              ( !LDD  '1A<G,M,C R,3 X,#1?<')E+GAM;%!+!08
1    !0 % % !  #"4      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
